Article: Finding a (biomarker) needle in the haystack
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
List view / Grid view
Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.
Children with multisystem inflammatory syndrome have a unique immunological profile revealed by systems-level analyses.
Several recent studies highlight the promise of combining genomics and proteomics to uncover new, robust drug targets.
Why you should link genomics with proteomics to accelerate the search for effective drug targets.